本帖最后由 老马 于 2012-1-13 21:20 编辑 ) ?( s' W# [* m0 U
" j5 f% V, o2 n, b2 e爱必妥和阿瓦斯丁的比较9 J' e( J5 ~4 @( x8 ~. |8 b
4 ]( g( h, \7 J$ w
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 J& a( F$ R% f9 Q' a
$ V' F8 [1 M1 H: T9 D
! [' ~- i/ {7 S7 |/ C% a. `http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. j+ j; l1 j, f5 G& {
==================================================& R3 x' _/ i" x4 b& s: ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# L3 Z7 }4 F1 O1 B$ z) z$ Z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.9 A- B6 g, R0 M9 v# f
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 y, O. B( D) B
|